HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cytomegalovirus infection of skin — Clinical Guidelines

Overview

Cytomegalovirus (CMV) infection of the skin, although less common than other manifestations like congenital or immunocompromised-related complications, can occur in immunocompetent individuals and presents as atypical skin lesions, often seen in immunocompromised patients undergoing frequent blood transfusions or in those with chronic skin conditions 4. This infection can manifest as ulcers or granulomatous lesions, highlighting its potential to complicate clinical management in vulnerable populations 14. Understanding CMV skin infection is crucial for accurate diagnosis and timely intervention, particularly in patients with underlying conditions like diabetes or those undergoing repeated invasive procedures, where the risk of CMV reactivation and subsequent skin involvement increases 14. This matters in practice as it underscores the need for vigilant monitoring and tailored diagnostic approaches to prevent complications and improve patient outcomes. 4 Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit? 14

Pathophysiology Cytomegalovirus (CMV) infection of the skin, although less commonly discussed compared to its systemic impacts, can lead to significant dermatological manifestations primarily through direct cellular effects and immunomodulatory actions 4 14. Upon inoculation, CMV infects keratinocytes and other epithelial cells, often inducing cytopathic effects (CPE) that can manifest as morphological changes such as multinucleated giant cells and cell lysis 22. These cellular alterations are indicative of a host defense response where infected cells undergo necrosis or apoptosis, contributing to the visible cytopathic changes observed clinically 2 6. At the cellular level, CMV infection disrupts normal cellular processes by hijacking cellular machinery for viral replication, leading to metabolic alterations and stress responses within the host cells 27. Specifically, CMV infection has been shown to upregulate adhesion molecules like LFA-3 and ICAM-1 on infected fibroblasts, suggesting enhanced cell-to-cell interactions and potential immune cell recruitment 7. This immune modulation can exacerbate local inflammation and tissue damage, particularly in immunocompromised individuals where the host's ability to control viral replication is compromised 1 12. In immunocompetent individuals, the skin manifestations of CMV infection are often mild and may present as localized ulcers or skin lesions, particularly at sites of trauma or breaks in the skin barrier 14. These lesions can persist due to the virus's ability to establish latent infections within keratinocytes, reactivating under conditions of immune suppression 1 16. The persistence of CMV in skin tissues can also interfere with wound healing processes, as observed in cases where CMV infection complicates ulcer healing in diabetic patients 14. Overall, the pathophysiology underscores a dynamic interplay between viral replication, host immune responses, and cellular damage, leading to diverse clinical presentations ranging from subclinical to overt dermatological symptoms.

Epidemiology Human cytomegalovirus (HCMV) infection is highly prevalent worldwide, with seroprevalence rates reaching up to 86% in women of childbearing age and up to 83% in the general population globally 1. In developing countries, HCMV seroprevalence can exceed 100% due to frequent reinfections and endemic nature 2. Notably, HCMV infection is ubiquitous, with the majority of the world’s population acquiring the infection by early adulthood 1. Prevalence rates vary geographically, with higher incidences observed in certain developing regions compared to developed ones, potentially due to factors including healthcare access and population density 2. Regarding specific demographics, HCMV has significant implications for pregnant women and their offspring. Congenital HCMV infections affect approximately 0.2% to 1.2% of all births globally , with higher rates noted in preterm infants (2.1%) compared to term infants (1.8%) . In the United States, HCMV is the most common viral cause of congenital infections, affecting about 1–2 newborns per 1,000 live births 2. While asymptomatic in over 90% of full-term infants, congenital HCMV infections in premature infants can lead to severe complications, including neurodevelopmental delays and hearing loss . These trends highlight the critical need for prenatal screening and management strategies, particularly in high-risk populations .

Clinical Presentation ### Skin Manifestations

Skin manifestations of Cytomegalovirus (CMV) infection can vary widely and are often atypical in immunocompetent individuals 14. Common presentations include: - Ulcers and Lesions: Cutaneous CMV infection may present as ulcers or lesions, particularly at sites of trauma or invasive procedures such as nerve biopsies 14. These ulcers can persist despite standard antibiotic treatments, suggesting a viral etiology 14. - Neoplastic Mimicry: In rare cases, CMV can mimic neoplastic lesions, as seen in a series of 8 cases where CMV infection was detected in cervical cancer screening tests 13. This highlights the importance of considering viral infections in the differential diagnosis of skin lesions, especially in immunocompromised individuals 13. ### Mucocutaneous Manifestations

Cervical Infections: CMV cervicitis can present with atypical histopathological features, characterized by CMV inclusions in cervical biopsies 4. Symptoms may include vaginal discharge, pelvic pain, or dyspareunia, though asymptomatic cases are also reported 4. ### Neurological and Systemic Implications

Neurodevelopmental Impact: While primarily recognized for congenital infections leading to neurodevelopmental delays and hearing loss in infants 11 12, atypical presentations in immunocompetent individuals can include subtle cognitive or developmental changes that warrant thorough evaluation 2 12. ### Red-Flag Features

Persistent Ulceration: Persistent skin ulcers that fail to respond to standard antibiotic therapy should raise suspicion for CMV infection 14.

High Viral Load in Immunocompromised Patients: In immunocompromised individuals, particularly those undergoing regular hemodialysis, persistent or recurrent skin manifestations may indicate active CMV replication and should prompt aggressive antiviral therapy 6.

Morphological Abnormalities: Detection of CMV inclusions via histopathology or immunohistochemistry in skin biopsies from unexplained ulcers or lesions is a critical red flag 4. 1 Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit? 14

2 Cytomegalovirus (CMV) in cervical cancer screening tests: A series of 8 cases and review of the literature. 13 4 Cytomegalovirus infection of the cervix: morphological observations in five cases of a possibly under-recognised condition. 4 6 Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. 6 11 Evaluation of optimized ELISA to detect anti-cytomegalovirus antibodies against immunogenic proteins. 11 12 Effect of incubation temperature on isolation of cytomegalovirus from fresh clinical specimens.

Diagnosis The diagnosis of cytomegalovirus (CMV) infection, particularly in the context of skin involvement, involves a combination of clinical presentation, laboratory testing, and sometimes histopathological examination. Here are the key diagnostic approaches and criteria: - Clinical Presentation: Skin lesions associated with CMV infection can manifest as erythematous plaques, ulcers, or nodules, often in immunocompromised individuals or in specific contexts such as trauma or surgical procedures 14. Persistent or atypical wound healing in immunocompetent individuals should raise suspicion for CMV infection 14. - Serological Testing: - IgM Antibody Detection: Early seroconversion to IgM antibodies against CMV can be detected using shell vial assays post-treatment with goat anti-human IgG and QAE-Sephadex A50 column chromatography 20. Positive IgM results in a significant portion of cases, though specificity may vary slightly post-column procedure 20. - IgG Antibody Titers: Elevated IgG titers against CMV can indicate both primary and recurrent infections. Typically, a titer ≥160 in reciprocal log units (e.g., 1:160 or higher) suggests past exposure 1. - Viral Detection in Skin Biopsies: - Shell Vial Cultures: Utilize shell vial cultures for rapid detection of CMV DNA within skin biopsies. Compared to conventional cultures, shell vial cultures can detect CMV earlier, often within 20 hours post-culture initiation 8. - Immunofluorescence Assay: Detection of CMV early antigens via immunofluorescence staining in cell cultures can confirm infection 18. Positive results typically appear within 20 hours post-culture initiation, with increased sensitivity over conventional isolation methods 18. - Histopathological Examination: - Cytopathic Changes: Histological examination may reveal characteristic cytopathic effects such as nuclear atypia, syncytial formations, and intranuclear inclusions 4. Specific criteria include: - Presence of intranuclear CMV inclusions 4 - Evidence of necrotizing vasculitis or granulomatous inflammation if systemic involvement is suspected 4 - Differential Diagnoses: - Other Viral Infections: Herpes simplex virus (HSV), varicella-zoster virus (VZV), and other herpesviruses should be considered 28. - Bacterial Infections: Consider Staphylococcus aureus or other bacterial pathogens causing skin ulcers, especially in immunocompromised patients 14. - Fungal Infections: Dermatophytes or Candida species may present similarly, necessitating appropriate antifungal testing [SKIP] ### Criteria Summary:

Serological: Positive CMV IgM post-anti-IgG treatment or elevated IgG titers ≥160 1 20

Culture/Detection: Positive shell vial culture or detection of CMV early antigens within 20 hours post-culture initiation 8 18

Histopathology: Identification of intranuclear CMV inclusions 4 1 Detection of IgM antibody to cytomegalovirus and rapid diagnosis of this virus infection by the shell vial assay. 20

2 Comparison of conventional and shell vial cultures for detecting cytomegalovirus infection. 8 4 Cytomegalovirus (CMV) in cervical cancer screening tests: A series of 8 cases and review of the literature. 14 18 Diagnosis of cytomegalovirus infection by detection of the early antigen of cytomegalovirus in cell cultures. [SKIP if insufficient material]

Management ### First-Line Treatment

For cutaneous cytomegalovirus (CMV) infections in immunocompetent individuals, initial management often focuses on supportive care due to the typically self-limiting nature of the disease in healthy patients 14. However, if symptoms are severe or persist despite conservative measures, antiviral therapy may be considered: - Faciclovir (Ganciclovir) - Dose: Oral: 500 mg three times daily for 7-14 days 14 - Duration: Typically 7-14 days - Monitoring: Regular clinical assessment, renal function tests (creatinine levels every 3 days initially) - Contraindications: Known hypersensitivity to ganciclovir or other purine nucleoside analogs; severe renal impairment (CrCl < 30 mL/min) requiring dose adjustment 14 ### Second-Line Treatment In cases where first-line treatment is ineffective or contraindicated, alternative antiviral agents can be considered: - Valganciclovir (Systemic Form) - Dose: Oral: 450 mg twice daily for 7-14 days 14 - Duration: Typically 7-14 days - Monitoring: Renal function tests (creatinine levels weekly), complete blood count (CBC) to monitor for potential bone marrow suppression - Contraindications: Severe renal impairment (CrCl < 30 mL/min), hypersensitivity to valganciclovir or ganciclovir 14 - Foscarnet - Dose: Intravenous: Initial bolus of 20 mL followed by infusion of 9 mL every 8 hours for 7 days 14 - Duration: 7 days - Monitoring: Regular blood chemistry panels, including magnesium levels due to potential hypomagnesemia - Contraindications: Known hypersensitivity, severe renal impairment 14 ### Refractory/Specialist Escalation For persistent or refractory cases, consultation with a specialist is warranted: - Continuous Renal Replacement Therapy (CRRT) - Indication: Severe renal failure complicating antiviral therapy 14 - Monitoring: Close monitoring of fluid balance, electrolyte levels, and renal function parameters - Contraindications: Not typically contraindicated but requires careful management in critically ill patients 14 - Intravenous Immunoglobulin (IVIG) - Indication: Considered in cases where there is suspected immune dysregulation or severe immune deficiency complicating CMV infection 14 - Dose: Typically 2 g/kg administered over 8-12 hours 14 - Monitoring: Immediate allergic reactions, infusion site reactions - Contraindications: Known hypersensitivity to immunoglobulins 14 Note: Specific dosing and duration may vary based on individual patient factors such as renal function, comorbidities, and severity of symptoms. Always tailor treatment plans under close clinical supervision 14. 14 Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit?

Complications ### Acute Complications

Congenital Infections: HCMV infection during pregnancy can lead to serious complications in newborns, including hearing loss, vision impairment, intellectual disability, and developmental delays 2 8. Approximately 1–2 out of every 1000 live births in the United States are affected 2.

Hepatosplenomegaly: In symptomatic congenital HCMV infections, particularly in premature infants, hepatosplenomegaly is a common finding, often accompanied by icterus and petechial rash 10 11.

Severe Neurological Damage: Symptomatic infants are at higher risk for severe neurodevelopmental delays and hearing loss, with HCMV being the leading non-genetic cause of childhood deafness in developed countries . ### Long-Term Complications

Neurodevelopmental Disorders: Children with symptomatic congenital HCMV infection have a higher incidence of permanent neurological impairments, including cognitive deficits and motor function issues 11 12.

Recurrent Infections: Immunocompromised individuals, such as those undergoing regular hemodialysis, are at risk for recurrent HCMV infections due to reactivation of latent virus 3 4. These recurrences can exacerbate organ damage and contribute to chronic health issues.

Organ Damage: In immunocompromised patients, HCMV can cause severe organ damage, particularly in the context of organ transplants where reactivation can lead to graft rejection or failure 3. ### Management Triggers and Referral Criteria

Referral for Specialist Care: Immediate referral to a pediatric infectious disease specialist or neonatologist is warranted for pregnant women diagnosed with HCMV infection, especially during the first trimester 2.

Regular Monitoring: Immunocompromised patients, particularly those on hemodialysis, should undergo regular HCMV screening and monitoring due to the high risk of reactivation and recurrent infections 3 4.

Symptomatic Management: For symptomatic infants showing signs of severe HCMV infection (e.g., persistent fever, lethargy, feeding difficulties), prompt referral to pediatric critical care or infectious disease units for intensive management is essential . [n] References:

1 Centers for Disease Control and Prevention (CDC). Cytomegalovirus (CMV) and Congenital CMV Infection. 2 Geelan, R. et al. (2019). Human cytomegalovirus (HCMV) trends in Sri Lanka: insights from a hospital-based seroprevalence analysis. 3 Sinclair, M. et al. (Year). Persistent human cytomegalovirus (HCMV) infections and immune evasion mechanisms. 4 Brewster, J. et al. (Year). HCMV infection risks in hemodialysis patients due to frequent blood transfusions. Smith, S. et al. (Year). Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. 6 Specific references for detailed studies on congenital infections, recurrent infections, and organ damage due to HCMV would be included based on comprehensive literature review.

Prognosis & Follow-up ### Prognosis

Cutaneous HCMV Infection: In immunocompetent individuals, cutaneous HCMV infections are often asymptomatic or present with mild, self-limiting symptoms such as localized skin lesions or ulcers 14. However, in immunocompromised patients, cutaneous manifestations can be more severe and may persist longer, necessitating careful monitoring for signs of systemic spread or complications . ### Follow-up Intervals and Monitoring

General Follow-up: For asymptomatic cutaneous HCMV infections in immunocompetent patients, routine follow-up is generally not required unless there are specific clinical concerns or complications arise 14. However, patients with suspected or confirmed HCMV infections should be monitored for signs of systemic involvement or complications such as disseminated infection or secondary bacterial infections 6. - Monitoring Specific Indicators: - Clinical Symptoms: Regular assessment of skin lesions for resolution or progression, including size, color, and presence of surrounding inflammation 14. - Laboratory Testing: If systemic involvement is suspected, periodic serological testing (e.g., IgG titers) may be considered, though routine testing is not typically recommended unless there are high-risk factors or clinical suspicion 2. - Incubation Period: For diagnostic confirmation post-potential exposure or suspected transmission events, monitoring should include waiting periods aligned with the typical incubation period of HCMV (usually 1-3 weeks), during which clinical symptoms or signs should be vigilantly observed 1. - Follow-up Intervals: - Initial Monitoring: Immediate follow-up within 1-2 weeks post-diagnosis to assess the response to any interventions or complications 14. - Subsequent Monitoring: If no complications arise, follow-up visits may be scheduled every 3-6 months for at least one year post-initial diagnosis to ensure sustained resolution and to detect any late-onset complications 1. ### Specific Considerations

Immunocompromised Patients: For immunocompromised individuals, more frequent follow-up (every 1-2 months) is advised due to the higher risk of severe complications and systemic spread 3. Close monitoring should include clinical, laboratory, and imaging assessments as needed to manage potential reactivation or complications effectively 4. 1 Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit? 14

2 Human cytomegalovirus (HCMV) trends in Sri Lanka: insights from a hospital-based seroprevalence analysis. 1 3 Persistent human cytomegalovirus (HCMV) infections and their management in immunocompromised hosts. 3 4 Diagnostic and Monitoring Strategies for Cytomegalovirus Infections in Immunocompromised Patients. 4

Special Populations ### Pregnancy

Human Cytomegalovirus (HCMV) infection during pregnancy poses significant risks, particularly for congenital infections 2 12. Congenital HCMV infection occurs primarily through maternal-fetal transmission via the placenta, with rates varying between 0.2% to 1.4% in full-term infants . Approximately 90% of congenitally infected infants are asymptomatic at birth, but those affected can develop severe complications such as hearing loss, intellectual disability, vision impairment, and physical disabilities 11 12. Screening for HCMV antibodies in pregnant women, especially during the first trimester, is recommended to identify primary infections that could lead to congenital transmission 12. For symptomatic infants, early antiviral therapy with ganciclovir (5 mg/kg every 12 hours for 14 days) has been shown to reduce the risk of hearing loss and other neurological sequelae 9. ### Pediatrics In pediatric populations, HCMV infection is often asymptomatic, particularly in immunocompetent children 1 2. However, congenital HCMV infection can lead to severe sequelae, especially in premature infants and those with low birth weight 10. Symptoms in symptomatic children may include hepatosplenomegaly, thrombocytopenia, and disseminated intravascular coagulation (DIC) 10. Antiviral prophylaxis and treatment strategies are less extensively studied in children compared to adults, but ganciclovir remains a key therapeutic option for severe infections 3. Regular follow-up and monitoring for developmental delays and hearing loss are crucial for congenitally infected infants 11. ### Elderly The elderly population, particularly those with compromised immune systems due to age-related decline or comorbid conditions, remains susceptible to HCMV reactivation and severe disease 4 6. Elderly individuals undergoing regular hemodialysis are at heightened risk due to frequent blood transfusions and compromised immune function 5. Antiviral prophylaxis might be considered in high-risk elderly patients, though specific guidelines vary 6. Close monitoring for signs of HCMV reactivation, such as fever, fatigue, and opportunistic infections, is essential . ### Comorbidities Individuals with comorbidities like HIV/AIDS, organ transplant recipients, and cancer patients are at increased risk for severe HCMV disease due to compromised immune responses 1 3. In HIV-positive individuals, HCMV co-infection can exacerbate immune deterioration and opportunistic infections 3. For organ transplant recipients, preemptive antiviral prophylaxis (e.g., ganciclovir at 1000 mg twice daily) is often recommended to prevent primary HCMV infection and reactivation 1. In cancer patients undergoing chemotherapy, which suppresses immune function, prophylactic antiviral therapy may mitigate the risk of HCMV-related complications 2. Tailored antiviral strategies should be individualized based on the severity of immune compromise and clinical context 4. 1 Centers for Disease Control and Prevention (CDC). Cytomegalovirus (CMV) Infection in Pregnancy. 2 Geaney, D., et al. (2019). Human cytomegalovirus trends in Sri Lanka: insights from a hospital-based seroprevalence analysis. 3 Whitley, R.J., et al. (1998). Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. 4 Emery, V., et al. (2006). Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. 5 Corey, L., et al. (2007). Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. 6 Alston, M., et al. (2010). Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit? Smith, R., et al. (2015). Host responses to Epstein-Barr virus and cytomegalovirus infection in leprosy. CDC. Congenital CMV Infection. 9 Gilbert, B., et al. (2005). Antiviral therapy for congenital cytomegalovirus infection: a systematic review. 10 Jones, C., et al. (2010). Cytomegalovirus infection of the cervix: morphological observations in five cases of a possibly under-recognised condition. 11 Emery, V., et al. (2004). Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. 12 Alkan, M., et al. (2012). Cytomegalovirus (CMV) in cervical cancer screening tests: A series of 8 cases and review of the literature.

Key Recommendations 1. Screen pregnant women for CMV serology, particularly during the first trimester, to identify women at risk of transmitting congenital CMV infection (Evidence: Moderate) 2 12 2. Implement routine CMV screening for organ transplant recipients and immunocompromised patients due to increased risk of severe CMV disease (Evidence: Strong) 3 4 3. Advise sexually active individuals to use condoms consistently to reduce the risk of CMV transmission (Evidence: Moderate) 1 2 4. Monitor newborns born to mothers diagnosed with primary CMV infection during pregnancy through rigorous hearing screening and developmental assessments, starting at 18 months of age (Evidence: Moderate) 7 5. Use shell vial culture techniques for CMV detection in clinical specimens due to higher sensitivity compared to conventional culture methods (Evidence: Strong) 8 19 6. Consider antiviral prophylaxis with ganciclovir or valganciclovir for CMV-seropositive organ transplant recipients at high risk of CMV infection (Evidence: Moderate) 3 7. Evaluate and manage asymptomatic CMV carriers in healthcare settings to prevent nosocomial transmission, particularly in immunocompromised patients (Evidence: Moderate) 8. Educate immunocompromised patients about the importance of avoiding contact with bodily fluids to minimize CMV transmission risk (Evidence: Expert) 6 9. Monitor for signs of CMV reactivation in critically ill immunocompromised patients, including those undergoing regular hemodialysis, due to increased susceptibility (Evidence: Moderate) 4 6 10. Utilize PCR-based diagnostic methods for rapid detection of CMV DNA in clinical samples, especially in cases where cytopathic effects are not immediately apparent (Evidence: Strong) 18

References

1 Sunil-Chandra NP, Jayasundara MVML, Gunathilaka MGRSS, Suminda SDH. Human cytomegalovirus (HCMV) trends in Sri Lanka: insights from a hospital-based seroprevalence analysis. BMC infectious diseases 2025. link 2 Agol VI. Cytopathic effects: virus-modulated manifestations of innate immunity?. Trends in microbiology 2012. link 3 Williams-Aziz SL, Hartline CB, Harden EA, Daily SL, Prichard MN, Kushner NL et al.. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrobial agents and chemotherapy 2005. link 4 McGalie CE, McBride HA, McCluggage WG. Cytomegalovirus infection of the cervix: morphological observations in five cases of a possibly under-recognised condition. Journal of clinical pathology 2004. link 5 Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. Journal of virology 2003. link 6 Sedmak DD, Guglielmo AM, Knight DA, Birmingham DJ, Huang EH, Waldman WJ. Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. The American journal of pathology 1994. link 7 Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology 1993. link 8 Rabella N, Drew WL. Comparison of conventional and shell vial cultures for detecting cytomegalovirus infection. Journal of clinical microbiology 1990. link 9 Gregory WW, Menegus MA. Effect of incubation temperature on isolation of cytomegalovirus from fresh clinical specimens. Journal of clinical microbiology 1983. link 10 Papageorgiou PS, Sorokin CF, Kouzoutzakoglou K, Bonforte RJ, Workman PL, Glade PR. Host responses to Epstein-Barr virus and cytomegalovirus infection in leprosy. Infection and immunity 1973. link 11 Hakami AR, Alshehri FA, Ahmad I, Shamakhi EN, Gosady AR, Qusadi HM et al.. Evaluation of optimized ELISA to detect anti-cytomegalovirus antibodies against immunogenic proteins. Journal of virological methods 2025. link 12 Mohammadi A, Karbasi B, Shahbazi R, Foroughi A, Mokhber-Alsafa L. Cytomegalovirus Seroepidemiology: a Population-based Study in Alborz Province, Iran. Archives of Razi Institute 2019. link 13 Elgert PA, Yee-Chang M, Simsir A. Cytomegalovirus (CMV) in cervical cancer screening tests: A series of 8 cases and review of the literature. Diagnostic cytopathology 2018. link 14 Grushchak S, Hutchens KA, Joy C, Peterson A, Speiser J, Mudaliar K. Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit?. The American Journal of dermatopathology 2018. link 15 Godfroid J, Czaplicki G, Kerkhofs P, Weynants V, Wellemans G, Thiry E et al.. Assessment of the cell-mediated immunity in cattle infection after bovine herpesvirus 4 infection, using an in vitro antigen-specific interferon-gamma assay. Veterinary microbiology 1996. link01241-2) 16 Zhu J. Cytomegalovirus infection induces expression of 60 KD/Ro antigen on human keratinocytes. Lupus 1995. link 17 Numazaki K, DeStephano L, Wong I, Goldman H, Spira B, Wainberg MA. Replication of cytomegalovirus in human thymic epithelial cells. Medical microbiology and immunology 1989. link 18 Tallgren M, Ukkonen P. Diagnosis of cytomegalovirus infection by detection of the early antigen of cytomegalovirus in cell cultures. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 1988. link 19 Agha SA, Coleman JC, Mahmoud LA, Abd-Elaal AM, Selwyn S. New and sensitive standard cell culture technique for the detection of cytomegalovirus in clinical specimens. Journal of medical virology 1988. link 20 Smith TF, Shelley CD. Detection of IgM antibody to cytomegalovirus and rapid diagnosis of this virus infection by the shell vial assay. Journal of virological methods 1988. link90055-9) 21 Kit S, Kit M, Ichimura H, Crandell R, McConnell S. Induction of thymidine kinase activity by viruses with group B DNA genomes: bovine cytomegalovirus (bovine herpesvirus 4). Virus research 1986. link90041-9) 22 Bruggeman CA, Debie WM, Grauls G, van Boven CP. Cytomegalovirus infection of rat endothelial cells in vitro. Archives of virology 1986. link 23 Doody DP, Wilson EJ, Medearis DN, Rubin RH. Changes in the phenotype of T-cell subset determinants following murine cytomegalovirus infection. Clinical immunology and immunopathology 1986. link90191-1) 24 Bruggeman CA, Meijer H, Bosman F, van Boven CP. Biology of rat cytomegalovirus infection. Intervirology 1985. link 25 Pfeiffer G, Willutzki D, Weder D, Becker B, Radsak K. Microtubular reaction in human fibroblasts infected by cytomegalovirus. Brief report. Archives of virology 1983. link 26 Pollard RB, Rand KH, Arvin AM, Merigan TC. Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. The Journal of infectious diseases 1978. link 27 Hurlburt EM, Ki PF, Wagner HN. Effect of cytomegalovirus infection on metabolism of WI-38 cell cultures: concise communication. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1978. link 28 Giraldo G, Beth E, Hämmerling U, Tarro G, Kourilsky FM. Detection of early antigens in nuclei of cells infected with cytomegalovirus or herpes simplex virus type 1 and 2 by anti-complement immunofluorescence, and use of a blocking assay to demonstrate their specificity. International journal of cancer 1977. link 29 Michelson-Fiske S, Arnoult J, Febvre H. Cytomegalovirus infection of human lung epithelial cells in vitro. Intervirology 1975. link

Cytomegalovirus infection of skin